Hisamitsu Pharmaceutical Co., Inc. manufactures and sells pharmaceuticals, quasi-drugs, and medical devices in Japan. The company provides external pain relieving drugs under the SALONPAS, NOBINOBI, SALONSIP, AIR, SALONPAS, and FEITAS; and BUTENALOCK, a remedy for athlete's foot, as well as ALLEGRA FX, a sinus medication for allergies. It also manufactures and sells quasi-drugs and cosmetics; MOHRUS TAPE and MOHRUS PAP XR, transdermal analgesic anti-inflammatory drug; patches for female hormone, asthma treatment, and treatment for overactive bladders. In addition, the company manufactures and sells drugs under MOHRUS TAPE, MOHRUS PAP XR, FENTOS Tapes, NEOXY Tapes, Abstral, ALLESAGA Tapes, HARUROPI Tapes, and MENOAID Combipatch. Further, it provides HFT-290, a transdermal patch for cancer pain. The company sells its products in the United States and Asia. Hisamitsu Pharmaceutical Co., Inc. was founded in 1847 and is headquartered in Tosu, Japan.
Hisamitsu Pharmaceutical Dividend Announcement
• Hisamitsu Pharmaceutical announced a semi annually dividend of ¥45.00 per ordinary share which will be made payable on 2025-05-01. Ex dividend date: 2025-02-27
• Hisamitsu Pharmaceutical's trailing twelve-month (TTM) dividend yield is 1.96%
• Hisamitsu Pharmaceutical's payout ratio for the trailing twelve months (TTM) is 10.98%
Hisamitsu Pharmaceutical Dividend History
Ex-Div date | Dividend amount | Dividend type | Pay date |
---|---|---|---|
2025-02-27 | ¥45.00 | semi annually | 2025-05-01 |
2024-08-29 | ¥43.00 | semi annually | 2024-08-29 |
2024-02-28 | ¥42.50 | semi annually | |
2023-08-30 | ¥42.50 | semi annually | 2023-11-07 |
2023-02-27 | ¥0.25 | semi annually | 2023-05-29 |
2022-08-30 | ¥0.25 | semi annually | 2022-11-09 |
2022-02-25 | ¥42.00 | semi annually | 2022-05-27 |
2021-08-30 | ¥42.00 | semi annually | 2021-11-11 |
2021-02-25 | ¥41.75 | semi annually | 2021-05-28 |
2020-08-28 | ¥41.75 | semi annually | 2020-11-05 |
2020-02-27 | ¥41.50 | semi annually | 2020-05-22 |
2019-08-29 | ¥41.50 | semi annually | 2019-11-07 |
2019-02-26 | ¥41.25 | semi annually | 2019-05-24 |
2018-08-29 | ¥41.25 | semi annually | 2018-11-07 |
2018-02-26 | ¥41.00 | semi annually | 2018-05-25 |
2017-08-29 | ¥41.00 | semi annually | 2017-11-07 |
2017-02-24 | ¥41.00 | semi annually | 2017-05-26 |
2016-08-29 | ¥40.50 | semi annually | |
2016-02-25 | ¥1.00 | semi annually | |
2015-08-27 | ¥40.00 | semi annually | |
2015-02-25 | ¥42.50 | semi annually | |
2014-08-27 | ¥37.50 | semi annually | |
2014-02-26 | ¥5.00 | semi annually |
Hisamitsu Pharmaceutical Dividend per year
Hisamitsu Pharmaceutical Dividend growth
Hisamitsu Pharmaceutical Dividend Yield
Hisamitsu Pharmaceutical current trailing twelve-month (TTM) dividend yield is 1.96%. Interested in purchasing Hisamitsu Pharmaceutical stock? Use our calculator to estimate your expected dividend yield:
Hisamitsu Pharmaceutical Financial Ratios
Hisamitsu Pharmaceutical Dividend FAQ
Other factors to consider when evaluating Hisamitsu Pharmaceutical as a dividend stock include its dividend yield, dividend growth, payout ratio, and the sustainability of its dividend payments given its earnings and cash flow. These factors can provide insight into the company's ability to maintain or increase its dividend in the future.
Place an order: Use the brokerage's trading platform to place an order to buy Hisamitsu Pharmaceutical stock.
Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.
1. Determination of Dividend: Hisamitsu Pharmaceutical's board of directors reviews the company's financial performance, cash flow, future investment needs, and other relevant factors to determine the amount and timing of dividend payments.
2. Dividend Declaration: Once the board approves a dividend, Hisamitsu Pharmaceutical publicly announces the dividend amount, currency, and the ex-dividend date. The ex-dividend date is the date on or after which the buyer of the stock will not be eligible to receive the upcoming dividend payment.
3. Record Date: The record date is the date on which the company checks its records to identify shareholders who are eligible to receive the dividend. Only shareholders on record as of this date will receive the dividend.
4. Payment Date: On the designated payment date, Hisamitsu Pharmaceutical distributes the dividend to eligible shareholders. The dividend is usually paid in the form of cash directly into the shareholder's brokerage account or through other designated payment methods.
5. Tax Implications: Dividends received from Hisamitsu Pharmaceutical are generally taxable as income. Shareholders may need to report dividend income on their tax returns and pay applicable taxes according to their jurisdiction's tax regulations.
1. Record Date: Hisamitsu Pharmaceutical sets a record date, which is the date on which the company checks its records to determine the eligible shareholders. Only those who are shareholders on record as of this date will receive the dividend.
2. Payment Date: On the designated payment date, Hisamitsu Pharmaceutical distributes the dividend to eligible shareholders. The payment is usually made electronically, directly into the shareholder's brokerage account or bank account.
3. Currency: Hisamitsu Pharmaceutical declares the currency in which the dividend will be paid. Depending on the shareholder's location and the currency election made by the shareholder, the dividend will be converted to the appropriate currency during the payment process.
To assess the safety of Hisamitsu Pharmaceutical's dividend, it is crucial to analyze the company's financial health, debt levels, cash flow generation, and ability to sustain dividend payments over the long term. Additionally, monitoring the company's future earnings, cash flow projections, and management's commitment to dividend policies can provide valuable insights.
It is recommended to review Hisamitsu Pharmaceutical's financial reports, official announcements, and consult with financial advisors or experts who have access to the most current and comprehensive information about the company's financial situation.